Repression of MiR-142 by P300 and MAPK is Required for Survival Signalling Via Gp130 During Adaptive Hypertrophy
Overview
Affiliations
An increase in cardiac workload, ultimately resulting in hypertrophy, generates oxidative stress and therefore requires the activation of both survival and growth signal pathways. Here, we wanted to characterize the regulators, targets and mechanistic roles of miR-142, a microRNA (miRNA) negatively regulated during hypertrophy. We show that both miRNA-142-3p and -5p are repressed by serum-derived growth factors in cultured cardiac myocytes, in models of cardiac hypertrophy in vivo and in human cardiomyopathic hearts. Levels of miR-142 are inversely related to levels of acetyltransferase p300 and MAPK activity. When present, miR-142 inhibits both survival and growth pathways by directly targeting nodal regulators p300 and gp130. MiR-142 also potently represses multiple components of the NF-κB pathway, preventing cytokine-mediated NO production and blocks translation of α-actinin. Forced expression of miR-142 during hypertrophic growth induced extensive apoptosis and cardiac dysfunction; conversely, loss of miR-142 fully rescued cardiac function in a murine heart failure model. Downregulation of miR-142 is required to enable cytokine-mediated survival signalling during cardiac growth in response to haemodynamic stress and is a critical element of adaptive hypertrophy.
MicroRNA-142 regulates gut associated lymphoid tissues and group 3 innate lymphoid cells.
Roberts L, Neves J, Lee D, Valpione S, Tacho-Pinot R, Howard J Mucosal Immunol. 2024; 18(1):39-52.
PMID: 39245145 PMC: 11835792. DOI: 10.1016/j.mucimm.2024.09.001.
Chodkowska K, Barszcz M, Tusnio A Sci Rep. 2024; 14(1):4413.
PMID: 38388757 PMC: 10884404. DOI: 10.1038/s41598-024-54915-y.
Role of miRNA in Cardiovascular Diseases in Children-Systematic Review.
Paslawska M, Grodzka A, Peczynska J, Sawicka B, Bossowski A Int J Mol Sci. 2024; 25(2).
PMID: 38256030 PMC: 10816020. DOI: 10.3390/ijms25020956.
miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.
Huang W, Paul D, Calin G, Bayraktar R Cells. 2024; 13(1).
PMID: 38201290 PMC: 10778542. DOI: 10.3390/cells13010084.
Advances in the study of miRNAs in chronic kidney disease with cardiovascular complications.
Zou C Front Physiol. 2023; 14:1283597.
PMID: 38074330 PMC: 10701263. DOI: 10.3389/fphys.2023.1283597.